Skip to content

Study for the change of salivary cortisol in different time of Uygur hypertension with obesity patients

Study for the change of salivary cortisol in different time of Uygur hypertension with obesity patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OON-14005628
Enrollment
Unknown
Registered
2014-10-05
Start date
2014-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension and Obesity

Interventions

five-groups:no

Sponsors

TCM Hospital of Xinjiang Autonomous Region
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Hypertension with obesity group (1) comply with hypertension with obesity diagnostic criteria: Obesity occurs before hypertension; BMI more than 28Kg/m2; SBPhigher than 140mmHg or DBP higher than 90mmHg; (2) to be aged from 40 years to 65 years; (3) Signed informed consent. 2. Obesity group (1) BMI more than 28Kg/m2; (2) No hypertension; (3) to be aged from 40 years to 65 years; (4) Signed informed consent. 3. Healthy control group: (1) BMI from 18.5Kg/m2 to 24Kg/m2; (2) No hypertension; (3) to be aged from 40 years to 65 years; (4) Signed informed consent. 4. Hypertension without obesity group: (1) BMI between 18.5Kg/m2 to 24Kg/m2; (2) hypertension; (3) to be aged from 40 years to 65 years; (4) Signed informed consent. 5. Cushing's syndrome group: (1) If the clinical manifestations consistent with CS, the 24h-UFC more than 5 times of upper limit of normal, no other checks can be confirmed. Results suspicious, to be 48h-LDDST confirmed; (2) late-night salivary more than 4 nmol/L (145 ng/dL); (3) midnight plasma cortisol more than 50 nmol/L (1.8 mg/dL); such less than 1.8 mg/dL, can be excluded CS; (4) overnight 1mg-LDDST serum cortisol more than 1.8 mg/dL; (5) Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. With severe heart and brain and kidney and hematopoietic system diseases; 2. Mental disorders, with anxiety, depression, those with no insight, who can not express; 3. Other patients participating in clinical trials; 4. Not signed informed consent.

Design outcomes

Primary

MeasureTime frame
Salivary cortisol;blood pressure;BMI;

Secondary

MeasureTime frame
blood lipids;glucose;

Countries

China

Contacts

Public ContactXu Hongfeng
xuhongfenghero@126.com+86 15160986971

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026